ArticleBrain and behavior2026
Long-Term Secondary Preventive Medication Persistence and Adherence in Young Ischemic Stroke Survivors: A Prospective Single-Center Cohort Study.
Article in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionThe study aimed to evaluate long-term medication persistence and adherence to secondary prevention therapies in young ischemic stroke survivors (aged 18-49 years) and identify factors influencing these outcomes.
methodsThe single-center prospective cohort study enrolled young ischemic stroke patients (aged 18-49 years) from March 2017 to March 2023. Medication persistence (continuation of all prescribed secondary prevention drugs) and adherence (assessed by the Morisky Medication Adherence Scale-8 (MMAS-8)) were evaluated, with reasons for discontinuation and influencing factors analyzed.
resultsAmong 226 patients (median age 35 years, 34.5% female), 80.1% remained persistent with their medication regimen over a median follow-up of 3.9 years. Patients with persistence had higher rates of large artery atherosclerosis (42% vs. 22.2%, p = 0.015) and comorbid diabetes (13.3% vs. 2.2%, p = 0.015). The median MMAS-8 score was 7 (6-7.38), with 24.2% showing high adherence, 63% moderate adherence, and 12.8% poor adherence. Poor adherence was associated with younger age (<35 years, p = 0.018), the absence of large artery atherosclerosis (p = 0.017), and a lower quality of life (p = 0.004). Multivariate analysis revealed that older age (p = 0.043) and large artery atherosclerosis (p = 0.047) were independent predictors of better adherence.
conclusionYoung ischemic stroke patients demonstrated high medication persistence and moderate adherence, which were influenced by age, stroke etiology, and quality of life. These findings highlight the need for tailored secondary prevention strategies to improve outcomes in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.